TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All children between the ages of 2-5 years who meet diagnostic criteria for Autism or Pervasive Developmental Disorder by DSM IV criteria who are referred for treatment at Mifne for the treatment group.~* The control group will consist of children meeting the same criteria who are referred to Schneider Children's Medical Center of Israel (SCMCI). Matching will be for age, sex, ethnicity, socioeconomic status, IQ, language development and diagnosis.~Exclusion criteria:~* All referred children who do not meet criteria for Autism or PDD or do not understand Hebrew.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): Mifne Approach to PDD
- B (Type: OTHER): Treatment as usual

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Constructing an Insulin-Like Growth Factor-based Prediction Model

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Prepubertal patients,~* Male/female,~* Ages 3-14 yrs,~* Being treated with growth hormone for the conditions of growth hormone deficiency, idiopathic short stature, and small-for-gestational age with failure to catch up to the normal growth curve by age 2 years.~Exclusion Criteria:~* Patients being treated with growth hormone for other conditions such as Turner syndrome, chronic renal failure, or Prader-Willi syndrome

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women over 18 years of age~* Patients with a histologically confirmed diagnosis of pancreatic cancer with borderline resectable or locally advanced disease~* Receiving stereotactic body radiation therapy for pancreatic cancer with active breathing control (ABC)~* Able to read and write in English or able to understand/answer study questions and instructions with the aid of an interpreter~Exclusion Criteria:~* Patients who do not provide informed consent~* Patients who chose not to answer the study questions~* Patients who chose not to use the xR device and platform~* Patients with a seizure history

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABC technique plus biofeedback (Type: EXPERIMENTAL): Patients will utilize biophysical feedback and coaching during the planning and treatment sessions for radiotherapy to help patients with the ABC technique.
- Standard of care ABC technique. (Type: ACTIVE_COMPARATOR): Patients will standard of care instructions for using the ABC technique during the planning and treatment sessions for radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Pain Control Following Renal Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral renal transplant~Exclusion Criteria:~* History of chronic pain, chronic opioid use, or opioid use disorder~* Cardiac arrythmia, cardiac failure~* Hepatic Failure~* Local anesthetic allergy (allergy to lidocaine and ropivacaine)~* Complicated surgical course including intraoperative damage to other organs (bowel)~* Return to operating room within 72hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous Lidocaine (Type: EXPERIMENTAL): None
- Transversus abdominis plane (TAP) block (Type: ACTIVE_COMPARATOR): None
- Quadratus Lumborum (QL) Block (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Detection of K14 in Bladder Cancer With a Non Invasive Technique

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Bladder cancer~Exclusion Criteria:~* Inability to sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bladder cancer (Type: None): Patients who suffered a bladder cancer
- Control group (Type: None): Patients with urologic diseases of non tumoral origin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study: Utilizing Manometry to Assess Radiation-Induced Changes in Esophageal Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years or older~* Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)~* Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment~* Patients that will be treated with a minimum of 45 Gy of radiation therapy~* Patients with mediastinal nodal disease, or primary lesions that are near the esophagus are eligible provided that they are not having esophageal symptoms believed to be due to the tumor.~Exclusion Criteria:~* History of esophageal motility disorder that pre-dates and is unrelated to the present diagnosis of lung cancer~* History of any prior radiotherapy to the esophagus~* Pregnant or lactating women~* Inability to understand and follow swallowing instructions for the esophageal manometry procedure; this is to ensure patient compliance of performing the breath hold technique throughout the radiation therapy treatment~* Patients with mediastinal nodal disease, or primary lesions, that are having esophageal symptoms believed to be due to the tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Lung cancer patients ≥ 18 years of age (Type: None): Lung cancer patients age ≥ 18 years or older who have:~* Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment~* Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EVPOME Versus AlloDerm in Subjects Reconstructed With Large Defect Mandibular Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be an adult over 18 years of age~* Have a free fibular graft placed more than six months ago that has been used for restoration of mandibular continuity.~* Be in need of surgery to increase the vestibular fold of the grafted mandible for placement of a dental prosthesis to restore function~Exclusion Criteria:~* Any liver, kidney, heart, blood, metabolic or systemic disease which may make execution of the protocol of interpretation of the results difficult~* A history of syphilis, HIV, Hepatitis B or Hepatitis C~* Pregnancy or planning to become pregnant~* Known or suspected allergy to bovine (cow) protein~* Receiving radiation~* Currently smoking or using tobacco products~* Talking medication that can result in gingival enlargement (Cyclosporine, Dilantin, calcium channel blockers)~* Allergy to any of the following antibiotics Gentamycin, Cefoxitin, Lincomycin, Polymyxin B, Vancomycin, cephalosporins, or clindamycin~* Allergy to Polysorbate 20

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AlloDerm (Type: ACTIVE_COMPARATOR): The subject will be treated with the standard of care, AlloDerm, to cover the defect in the mouth.
- EVPOME (Type: EXPERIMENTAL): An ex-vivo produced oral mucose equivalent (EVPOME) will be used to cover the defect in the top of the mouth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Thigh Circumference Reduction Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index between 20 and 35~* Presence of cellulite grades II, III or IV according to GLD scale~* Visible bi-lateral thigh fat Thigh area to be treated to measure at least 30.0mm in vertical fold, as measured with industry standard fat caliper~* Subject must be able to read, understand and sign the Consent Form~* Subject must adhere to the follow-up schedule and study instructions~* Subject must adhere to the same diet and/or exercise routine throughout the study~Exclusion Criteria:~* Significant weight fluctuation (+/-10 lbs) in the past 6 months~* Taking weight-loss medications/supplements~* Participation in any other clinical study~* Cellulite treatment within 3 months of the treatment~* Surgical or non-surgical treatments to the target area in the last 12 months, e.g., liposuction~* Prior treatment to the target area within the last 12 months~* Arteriosclerosis or weakened blood vessels~* Heart disease~* Thromboembolic disease~* Diagnosed or documented immune system disorders~* Bleeding disorders.~* Presence of uncontrolled hypertension~* Taking prescription anticoagulants~* History of keloid formation~* Malignant tumors in the target area~* Diabetes~* Any disease or condition that could impair wound healing~* Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars~* Infection in the target area~* Implanted electrical device(s)~* Pregnant or lactating

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treated Thigh (Type: EXPERIMENTAL): The thigh treated with the RF device
- Untreated Thigh (Type: NO_INTERVENTION): The untreated thigh

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Postural Changes During Right Heart Catheterization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients that are 18 years or older regardless of gender or race,~* are referred for RHC for evaluation of possible Pulmonary Arterial Hypertension (PAH)~* provide informed consent~Exclusion Criteria:~* Inability to obtain pulmonary artery pressure or PCWP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Statins and Endothelial Function in Patients With Coarctation of the Aorta

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients over the age of 18 years with repaired coarctation of the aorta (CoA) and willing to participate in all portions of the study including follow up, blood draws, urine sample, echocardiogram, MRI, brachial artery flow-mediated dilatation (FMD) testing, Carotid Intima Media Thickness (CIMT) testing and statin administration.~Exclusion Criteria:~* patients who are pregnant, nursing, or planning on becoming pregnant in the subsequent year~* current smokers~* patients with documented coronary artery disease (CAD), other systemic inflammatory disorder such as systemic lupus erythematosis or rheumatoid arthritis~* patients already on statin therapy or who have had previous adverse effects to statin therapy~* patients with hepatic transaminases \>2X the upper limit of normal~* patients with creatinine clearance \<60mg/dL~* patients who have implanted devices such as pacemakers or defibrillators that preclude MRI testing~* patients with low blood pressure at baseline (\< 90/50)~* patients who are unwilling or unable to comply with the aforementioned portions of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- atorvastatin (Type: EXPERIMENTAL): Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy.
- sugar pill (Type: PLACEBO_COMPARATOR): See above. Patients will be randomized to atorvastatin vs. placebo for 12 weeks and after a 4 week washout period the groups will be switched.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: External Ionizing Radiation to Prevent Restenosis on Haemodialysis Vascular Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* over 18 years~* successful angioplasty (residual stenosis \< 30%) on a significant stenosis (maximal systolic speed 3 times \> from basal maximal systolic speed, stenosis \> 70% on angiography) on the venous-prosthesis anastomosis or on the venous segment 5 cm after the anastomosis of a prosthetic haemodialysis vascular access (at least 1 month old)~* social security affiliation~* signed informed consent~Exclusion Criteria:~* contra-indications of radiotherapy~* angioplasty with stenting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 14 Gy ionizing radiations
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Mesh Implantation in Patients With Peritonitis for the Prevention of Incisional Hernia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinical signs of peritonitis~* Emergency laparotomy or laparoscopy with conversion to laparotomy~* Patients \> 18 years~* Written informed consent~Exclusion Criteria~* Previous implanted mesh~* Incisional hernia present~* Small bowel obstruction without bowel resection~* Surgery for cholecystitis~* Inflammatory bowel disease (Crohn's disease, Ulcerative colitis)~* Polytrauma patients~* Pregnant women~* Women younger than 45 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Conventional abdominal wall closure with mesh implantation
- 2 (Type: NO_INTERVENTION): Conventional abdominal wall closure without mesh implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 years or older;~* positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for COVID-19 in a respiratory tract sample;~* intubated and mechanically ventilated;~* acute onset of ARDS, as defined by Berlin criteria as moderate-to-severe ARDS,3 which includes: (i) having pneumonia or worsening respiratory symptoms, (ii) bilateral pulmonary infiltrates on chest imaging (x-ray or CT scan), (iii) absence of left atrial hypertension, pulmonary capillary wedge pressure \<18 mmHg, or no clinical signs of left heart failure, and (iv) hypoxemia, as defined by a PaO2/FiO2 ratio of ≤200 mmHg on positive end-expiratory pressure (PEEP) of ≥5 cmH2O, regardless of FiO2.~Exclusion Criteria:~* Routine treatment with corticosteroids during the previous week irrespective of dose;~* Corticosteroid use within the previous 24 h of more than 20 mg of dexamethasone or equivalent;~* Patients with a known contraindication to corticosteroids;~* Decision by a physician that involvement in the trial is not in the patient's best interest;~* Pregnancy and breast-feeding;~* Participation in another therapeutic trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): Patients will be treated with standard intensive care
- Dexamethasone (Type: ACTIVE_COMPARATOR): Standard intensive care plus dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During Robot-Assisted Laparoscopic Radical Prostatectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for a Laparoscopic Radical Prostatectomy operation~* Patients must be between the ages of 35 and 75~* Patients must not have one of the above listed exclusion criteria~* Patients must be able to understand and willing to adhere to the study protocol~Exclusion Criteria:~* Patients less than 35 years of age and over 75 years of age~* Patients with previous rectal surgery~* Patients with anal stenosis that prevents the TRUS probe insertion~* Patients with extensive abdominal surgery~* Patients with inadequate bowel prep~* Patients who are unwilling or unable to sign informed consent~* Patients on anticoagulation medication (e.g., coumadin, lovenox, or heparin)

- Gender: MALE
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Device (Type: EXPERIMENTAL): Both the Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) and the Transrectal Ultrasound (TRUS) are common performed procedures, but are normally performed separately. In this proposed feasibility study, the procedures will be combined.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 38 Week Extension Study to CAIN457C2303

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~-~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- AIN457 300 mg every 2 weeks (Type: EXPERIMENTAL): None
- AIN457 300 mg monthly (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy